<DOC>
	<DOCNO>NCT00539760</DOCNO>
	<brief_summary>GSK182771 domain antibody target IL-1 receptor develop treatment rheumatoid arthritis . This study do healthy volunteer verify safety tolerability GSK182771</brief_summary>
	<brief_title>A Phase I Rheumatoid Arthritis Study Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Healthy adult men woman determine responsible physician , base medical evaluation include history , physical examination , laboratory test cardiac assessment . Female subject nonchildbearing potential . Male subject must agree abstain agree use adequate contraception , addition female partner use another form contraception . This criterion must follow time first dose study medication PK level determine LLQ . Men woman 18 55 year age , inclusive . BMI within range 1835 kg/m2 inclusive . Capable give write informed consent , include compliance requirement restriction list consent form The subject positive prestudy urine drug/urine alcohol screen . A minimum list drug screen include amphetamine , barbiturate , cocaine , opiates , cannabinoids benzodiazepine . A history regular alcohol consumption average &gt; 7 drinks/week female &gt; 14 drinks/week male . One drink equivalent ( 12 g alcohol ) = 5 ounce ( 150 mL ) wine 12 ounce ( 360 mL ) beer 1.5 ounce ( 45 mL ) 80 proof distil spirit The subject unwilling abstain alcohol consumption 48 hr prior dose discharge clinic , 48 hr prior outpatient clinic visit . Smoked used tobacco nicotinecontaining product within previous 6 month prior first dose current study medication . The subject participate clinical trial receive drug new chemical entity within 30 day 5 halflives , twice duration biological effect drug ( whichever longer ) prior first dose current study medication . Previous exposure treatment PEGylated molecule . Use antiTumor Necrosis Factor ( antiTNF ) drug within 60 day prior dose . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day , 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . History sensitivity study medication , component thereof , history drug allergy ( include antibiotic ) , opinion investigator and/or GSK Medical Monitor , contraindicate subject 's participation . Positive pregnancy test Screening Day 1 ( female ) . Any clinically significant abnormality identify screen medical assessment examination , ECG . Any WBC neutrophil count outside normal range screen Day 1 . History significant cardiac , pulmonary , metabolic , renal , hepatic , gastrointestinal condition opinion investigator and/or GSK Medical Monitor , place subject unacceptable risk participant trial . History autoimmune current inflammatory condition include rheumatoid arthritis joint disease . History malignancy , except surgically cure basal cell carcinoma cure cervical carcinoma ( &gt; 2 yr prior dose ) . Currently asthma history COPD . Current evidence ongoing acute infection . The subject history repeat , chronic opportunistic infection , opinion investigator and/or GSK Medical Monitor , place subject unacceptable risk participant trial . History Mycobacterium tuberculosis previous Mycobacterium infection . A positive prestudy Hepatitis B surface antigen , positive Hepatitis C antibody , HIV antibody test result . History severe allergic reaction , angioedema , anaphylaxis immunodeficiency History elevate blood pressure blood pressure &gt; 140/90 mmHg screening . Corrected QT interval ( QTc ) &gt; 450 msec . Where participation study would result donation blood excess 500 mL within 56 day start study . Subject whose calculated creatinine clearance le 80 mL/min Liver function test upper limit normal screening ( alkaline transaminase ( ALT ) , aspartate transaminase ( AST ) bilirubin ) . Chronic liver biliary disease , history Gilbert 's syndrome previous clinical study screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>domain antibody</keyword>
	<keyword>Rheumatoid Arthritis ,</keyword>
</DOC>